Cagrilintide + Semaglutide (5 mg + 5 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until fully dissolved (do not shake).
4. Label with date and refrigerate at 2 to 8 °C, protected from light; use within 30 days. Reconstitution math: 5 mg cagrilintide + 5 mg Semaglutide = 10 mg total blend; 10 mg ÷ 3.0 mL = 3.33 mg/mL total. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg total (16.7 mcg each peptide).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12+ months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week weekly protocol with gradual titration.

Peptide Vials (Cagri+Sema, 10 mg blend each):

• 8 weeks: ~1 vial (~6 mg total used).
• 12 weeks: ~2 vials (~14 mg total used).
• 16 weeks: ~3 vials (~27.6 mg total used).

Insulin Syringes (U-100):

• Per week: 1 syringe (once weekly).
• 8 weeks: 8. 12 weeks: 12. 16 weeks: 16.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (1 vial): 1 bottle. 12 weeks (2 vials): 1 bottle. 16 weeks (3 vials): 1 bottle.

Alcohol Swabs:

• Per week: 2 swabs. 16 weeks: 32 swabs (1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document weekly dose and site rotation to maintain consistency.
• Higher doses may increase GI side effects (nausea, reduced appetite); titrate gradually.

How This Works

Cagrilintide is a long-acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP-1 enhances pancreatic b-cell function and central appetite suppression. Clinical trials of the co-administered regimen (CagriSema) show greater body-weight reduction than either agent alone.

Benefits & Side Effects

Observations from clinical literature.

• Weight reduction: Phase 2 trials report mean body-weight loss of ~15 to 17% at 32 weeks with the

combination, exceeding Semaglutide monotherapy.

• Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss.
• GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration

minimizes severity.

• Injection-site reactions: mild and transient in clinical reports.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep and stress management to support adherence and recovery.
• Stay hydrated and eat slowly to reduce GI discomfort.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.

References

Source citations for further reading.

1. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with Semaglutide 2.4 mg in T2D: phase 2 trial (Lancet Diabetes Endocrinol, 2024).
2. Safety, tolerability, PK/PD of concomitant cagrilintide with Semaglutide 2.4 mg: phase 1b trial (Lancet, 2021).
3. Once-weekly cagrilintide for weight management: phase 2 trial in overweight/obesity (Lancet, 2021).
4. Efficacy and safety of CagriSema 2.4 mg + 2.4 mg in T2D (ScienceDirect, 2024).